Cascade Metrix (CMX) is a medical technology company working within a new paradigm in critical care. The company will introduce an Automated Multiplex Analyzer ["AutoPlexer"] that will revolutionize the bedside testing of hospitalized patients whose care and recovery is dependent on repetitive, around-the-clock measurements of critical blood parameters. This innovative and proprietary ex-vivo blood analysis system is first being applied to the automated multiplex measurement of glucose, lactate, hemoglobin and oxygen saturation in critically ill patients.
Latest Update: CMX was awarded a highly competitive SBIR Phase 1 grant funding (1R43GM146498-01; "A Multiplex Analyzer for Sepsis Management"; PI: Kislaya Kunjan, PhD) from National Institute of General Medical Sciences (NIGMS). (RePORTER.NIH.gov Portal). In addition to this, Elevate Ventures provided additional non-dilutive matching funds.
CMX has completed the prototypical development and preclinial validation of the AutoPlexer solution to support early diagnosis and treatment of sepsis. Efforts are currently underway for inpatient trials ahead of regulatory filings.
CMX is seeking investment as well as partnership opportunities with firms in the medical technology, health systems and related areas. Please contact